Literature DB >> 25303964

Correlation between EGFR mutation status and computed tomography features in patients with advanced pulmonary adenocarcinoma.

Jui-Sheng Hsu1, Ming-Shyan Huang, Chiao-Yun Chen, Gin-Chung Liu, Ta-Chih Liu, Inn-Wen Chong, Shah-Hwa Chou, Chih-Jen Yang.   

Abstract

PURPOSE: To correlate computed tomography (CT) imaging features and epidermal growth factor receptor (EGFR) mutation status in patients with advanced lung adenocarcinoma.
MATERIALS AND METHODS: Patients with advanced pulmonary adenocarcinoma who were diagnosed between January 1, 2009 and December 31, 2011 and who had available chest CT and their tumors analyzed for EGFR mutations at a university hospital were enrolled in this retrospective study. Two radiologists independently evaluated the CT images and recorded the target lesion's size, shape, margin, density, and the presence or absence of an air bronchogram and calcification.
RESULTS: One hundred and forty-nine patients were enrolled into this study (66 men, 83 women), with a mean age of 63±11 years (range 32 to 89 y). Seventy-eight (52.3%) patients had EGFR mutations. The tumors in the patients harboring no EGFR mutations (EGFR wild type) were larger than in those whose tumors harbored EGFR mutations (P=0.01). An irregular shape was more common in the tumors with wild-type EGFR (P=0.01), and an oval shape was more common in tumors with EGFR mutations. Tumors with exon 21 mutations were larger than those with exon 19 deletions (P=0.02). Air bronchograms were more common in tumors with exon 19 deletions than in those with wild-type EGFR or exon 21 mutations (P=0.004 and 0.01, respectively). Calcification was more common in the tumors with wild-type EGFR than in those with EGFR mutations (P=0.03).
CONCLUSIONS: Adenocarcinomas with wild-type EGFR were significantly associated with larger tumors and an irregular shape. In particular, calcification was more common in the tumors with wild-type EGFR than in those with EGFR mutations. In addition, air bronchograms were more common in the tumors with exon 19 deletions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25303964     DOI: 10.1097/RTI.0000000000000116

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  30 in total

Review 1.  NCTN Assessment on Current Applications of Radiomics in Oncology.

Authors:  Ke Nie; Hania Al-Hallaq; X Allen Li; Stanley H Benedict; Jason W Sohn; Jean M Moran; Yong Fan; Mi Huang; Michael V Knopp; Jeff M Michalski; James Monroe; Ceferino Obcemea; Christina I Tsien; Timothy Solberg; Jackie Wu; Ping Xia; Ying Xiao; Issam El Naqa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-01-31       Impact factor: 7.038

2.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Qian Li; Alberto L Garcia; Olya Stringfield; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2016-02-16       Impact factor: 4.785

3.  Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?

Authors:  Darragh F Halpenny; Andrew Plodkowski; Gregory Riely; Junting Zheng; Anya Litvak; Chaya Moscowitz; Michelle S Ginsberg
Journal:  Clin Imaging       Date:  2016-11-30       Impact factor: 1.605

4.  From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

Authors:  Andrew J Plodkowski; Alexander Drilon; Darragh F Halpenny; Dearbhail O'Driscoll; Donald Blair; Anya M Litvak; Junting Zheng; Chaya S Moskowitz; Michelle S Ginsberg
Journal:  Lung Cancer       Date:  2015-09-21       Impact factor: 5.705

5.  CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.

Authors:  Stefania Rizzo; Francesco Petrella; Valentina Buscarino; Federica De Maria; Sara Raimondi; Massimo Barberis; Caterina Fumagalli; Gianluca Spitaleri; Cristiano Rampinelli; Filippo De Marinis; Lorenzo Spaggiari; Massimo Bellomi
Journal:  Eur Radiol       Date:  2015-05-09       Impact factor: 5.315

6.  Predicting EGFR mutation status in lung cancer:Proposal for a scoring model using imaging and demographic characteristics.

Authors:  Ali Sabri; Madiha Batool; Zhaolin Xu; Drew Bethune; Mohamed Abdolell; Daria Manos
Journal:  Eur Radiol       Date:  2016-03-30       Impact factor: 5.315

7.  A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR-mutated lung adenocarcinoma.

Authors:  Y Cao; H Xu
Journal:  Curr Oncol       Date:  2018-04-30       Impact factor: 3.677

8.  A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD).

Authors:  Ying Zhu; Yu-Biao Guo; Di Xu; Jing Zhang; Zhen-Guo Liu; Xi Wu; Xiao-Yu Yang; Dan-Dan Chang; Min Xu; Jing Yan; Zun-Fu Ke; Shi-Ting Feng; Yang-Li Liu
Journal:  Ann Transl Med       Date:  2021-04

Review 9.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

Review 10.  Radiogenomics in brain, breast, and lung cancer: opportunities and challenges.

Authors:  Apurva Singh; Rhea Chitalia; Despina Kontos
Journal:  J Med Imaging (Bellingham)       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.